ARTICLE | Company News
Athersys, Pfizer deal
January 4, 2010 8:00 AM UTC
Athersys granted Pfizer rights to develop and commercialize Athersys' MultiStem to treat inflammatory bowel disease (IBD). The therapy composed of multipotent adult progenitor cells (MAPC) based on MultiStem technology is in preclinical testing for the indication. ...